Image Place holder

Brandon Blue, MD

Specialty: Hematology/Oncology

Program: Malignant Hematology

Overview


Associations

    • Malignant Hematology
    • Health Outcomes & Behavior Program

Education & Training

Fellowship:

  • Moffitt Cancer CenterBlood and Marrow Transplant and Cellular Immunotherapy
  • Saint Louis University School of MedicineHematology/Oncology

Residency:

  • Washington University School of Medicine - Internal Medicine

Medical School:

  • Meharry Medical College - MD
Research

Dr. Blue specializes in plasma cell disorders and evaluation and treatment of patients prior to and after stem cell transplantation. Dr. Blue has a research focus in outcomes research. His interest is to explore and eliminate health disparities as it relates to hematologic malignancies.

Publications

  • Peres LC, Colin-Leitzinger C, Teng M, Dutil J, Alugubelli RR, DeAvila G, Teer JK, Du D, Mo Q, Siegel EM, Hampton O, Alsina M, Brayer J, Blue B, Baz R, Siqueira Silva A, Nishihori T, Shain KH, Gillis N. Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma. Blood Adv. 2022 Jun.6(12):3767-3778. Pubmedid: 35500227. Pmcid: PMC9631567.
  • Blue B. Socioeconomic and Racial Disparity in Chimeric antigen receptor T cell (CART)Therapy Access. Transplant Cell Ther. 2022 Jul.28(7):345-346. Pubmedid: 35779944.
  • Zhang Y, Duncanson L, Brayer J, Reu F, Hansen D, Alsina M, Nishihori T, Ochoa-Bayona J, Liu H, Shain K, Thompson Z, Baz R, Blue B. Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study. Clin Lymphoma Myeloma Leuk. 2022 Aug.22(8):e770-e776. Pubmedid: 35504808.
  • Logue JM, Peres LC, Hashmi H, Colin-Leitzinger C, Shrewsbury AM, Hosoya H, Gonzalez R, Copponex C, Kottra KH, Hovanky V, Sahaf B, Patil S, Lazaryan A, Jain MD, Baluch A, Klinkova O, Bejanyan N, Faramand RG, Elmariah H, Khimani F, Davila ML, Mishra A, Blue B, Grajales-Cruz AF, Castaneda Puglianini O, Liu H, Nishihori T, Freeman CL, Brayer J, Shain KH, Baz R, Locke FL, Alsina M, Sidana S, Hansen DK. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022 Aug. Pubmedid: 35939783.
  • Fonseca JJ, Yeats AL, Blue B, Zalalutdinov MK, Brintlinger T, Simpkins BS, Ratchford DC, Culbertson JC, Grim JQ, Carter SG, Ishigami M, Stroud RM, Cress CD, Robinson JT. Enabling remote quantum emission in 2D semiconductors via porous metallic networks. Nat Commun. 2020 Jan.11(1):5. Pubmedid: 31911592. Pmcid: PMC6946668.
  • Blue B, Vegunta R, Rodin M, Patolia S, Poddar N. Impact of an Inpatient Palliative Care Consultation in Terminally Ill Cancer Patients. Cureus. 2018 Jul.10(7):e3016. Pubmedid: 30254805. Pmcid: PMC6150761.
  • Blue BJ, Luo S, Sanfilippo KM, Ganti A, Gumbel J, O'Brian K, Carson KR. Race-based differences in routine cytogenetic profiles of patients with multiple myeloma. Brit J Haematol. 2017 Jan.176(2):322-324. Pubmedid: 26887893.
  • Sanfilippo KM, Keller J, Gage BF, Luo S, Wang TF, Moskowitz G, Gumbel J, Blue B, O'Brian K, Carson KR. Statins Are Associated With Reduced Mortality in Multiple Myeloma. J Clin Oncol. 2016 Nov.34(33):4008-4014. Pubmedid: 27646948. Pmcid: PMC5477827.